Human papillomavirus vaccines: What does the future hold for preventing cervical cancer in resource-poor settings through immunization programs?

Sexually Transmitted Diseases

Volumn 32, Issue 10, 2005, Pages 635-640

  Jacob, Martha ^a   Bradley, Janet ^a   Barone, Mark A ^a  

^a ENGENDERHEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

UNCLASSIFIED DRUG; VIRUS VACCINE; WART VIRUS VACCINE;

CANCER IMMUNIZATION; CANCER SCREENING; CONDYLOMA; DRUG RESEARCH; ECONOMIC ASPECT; HEALTH PROGRAM; PREVENTIVE HEALTH SERVICE; REVIEW; SEXUALLY TRANSMITTED DISEASE; UTERINE CERVIX CANCER; WART VIRUS;

CERVICAL INTRAEPITHELIAL NEOPLASIA; DEVELOPING COUNTRIES; FEMALE; FORECASTING; HUMANS; IMMUNIZATION PROGRAMS; MEDICALLY UNDERSERVED AREA; PAPILLOMAVIRIDAE; PAPILLOMAVIRUS INFECTIONS; PAPILLOMAVIRUS VACCINES; UNITED STATES; UTERINE CERVICAL NEOPLASMS; VIRAL VACCINES;

EID: 26444474584     PISSN: 01485717     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.olq.0000179892.78342.79     Document Type: Review

References (79)

1. Ferlay J, Bray F, Pisani P, Parkin DM. GLOBOCAN 2002: Cancer Incidence, Mortality and Prevalence Worldwide. IARC CancerBase, no 5, version 2.0. Lyon: IARC Press, 2004.
2. Cullins VE, Wright TC, Beattie KJ, Pollack AE. Cervical cancer prevention using visual screening methods. Reprod Health Matters 1999; 7:134-143.
3. Sasieni P, Cuzick J, Faremery E. Accelerated decline in cervical cancer mortality in England and Wales. Lancet 1995; 346:1566-1567.
4. Miller AB, Linday J, Hill GB, et al. Mortality from cancer of the uterus in Canada and its relationship to screening for cancer of the cervix. Int J Cancer 1976; 17:602-612.
5. Hukama M, Chamberlain J, Day NE, Miller AB, Prorok. Evaluation of screening programs for gynecological cancer. Br J Cancer 1985; 52:669-673.
6. Austoker J. Cancer prevention in primary care-screening for cervical cancer. BMJ 1994; 309:241-248.
7. Herrero R, Schiffman MH, Hildesheim A, et al. Is cervical cancer cytological screening valuable in developing countries. In: Franco E, Monsonego J, eds. New Developments in Cervical Cancer Screening and Prevention. Monsonego: Blackwell Science Ltd, 1997:241-249.
8. Lazcano Ponce EC, Moss S, Alonso de Ruíz P, Salmerón Castro J, Hernández Avila M. Cervical cancer screening in developing countries: Why is it ineffective? The case of Mexico. Arch Med Res 1999; 30:240-250.
9. Koutsky LA, Ault KA, Wheeler CM, et al. A controlled trial of a human papillomavirus type 16 vaccine. N Engl J Med 2002; 347:1645-1651.
10. Munoz N, Bosch FX. The causal link between HPV and cervical cancer and its implications for prevention of cervical cancer. Bulletin of PAHO 1996; 30:362-377.
11. Walboomers JMM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999; 189:12-19.
12. Baay MF, Tjaima WA, Weyler J, et al. HPV infection in the female population of Antwerp, Belgium: Prevalence in healthy women, women with premalignant lesions and cervical cancer. Eur J Gynaecol Oncol 2001; 22:204-208.
13. Jansen KU, Shaw AR. Human papillomavirus vaccines and prevention of cervical cancer. Annu Rev Med 2004; 55:319-331.
14. Cates W Jr. Estimates of the incidence and prevalence of sexually transmitted diseases in the United States. The American Social Health Association Panel. Sex Transm Dis 1999; 26:S2-7.
15. Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papilloma virus infection in young women. N Engl J Med 1998; 338:423-428.
16. Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997; 102:3-8.
17. Nobbenhuis MAE, Walboomers JMM, Helmhorst TJM, et al. Relation of human papillomavirus status to cervical lesions and consequences for cervical cancer screening: A prospective study. Lancet 1999; 354:20-25.
18. Elfgren K, Kalantari M, Moberger B, Hagmar B, Dillner J. A population based five year follow up study of cervical human papillomavirus infection. Am J Obstet Gynecol 2000; 185:561-567.
19. Schlecht N, Kugala S, Robitaille J, et al. Persistent human papillomavirus infection as predictor of cervical intraepithelial neoplasia. JAMA 2001; 286:3106-3114.
20. Ellerbrock TV, Chiasson MA, Bush TJ, et al. Incidence of cervical squamous intraepithelial lesions in HIV-infected women. JAMA 2000; 283:1031-1037.
21. Remmink AJ, Wallboomers JMM, Helmhorst TM, et al. The presence of persistent HPV genotypes in dysplastic cervical lesions is associated with progressive disease: Natural history up to 36 months. Int J Cancer 1995; 61:306-311.
22. Hopman EH, Rosendaal L, Voorhorst FJ, Walboomers JMM, Kenemans P, Heimerhorst Th JM. High risk human papillomavirus in women with normal cervical cytology prior to the development of abnormal cytology and colposcopy. BJOG 2000; 107:600-604.
23. Munoz N, Bosch FX, Sanjose D, et al. Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med 2003; 348:518-527.
24. Liaw KL, Hildesheim A, Burk RD, et al. A prospective study of human papillomavirus (HPV) type 16 DNA detection by PCR and its association with acquisition and persistence of other HPV types. J Infect Dis 2001; 183:8-15.
25. Bosch FX, Manos M, Munoz N, et al. Prevalence of HPV in cervical cancer: a world wide perspective. J Natl Cancer Inst 1995; 87:796-802.
26. Clifford GM, Smith JS, Aguado T, Franceschi S. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: A metaanalysis. Br J Cancer 2003; 89:101-05.
27. Herrero R, Hildesheim A, Bratti C, et al. Population based study of HPV infection and cervical neoplasia in rural Costa Rica. J Natl Cancer Inst 2000; 92:464-474.
28. Chan PK, Li WH, Chan MY, et al. High prevalence of HPV type 58 in Chinese women with cervical cancer and precancerous lesions. J Med Virol 1999; 59:232-238.
29. Castellsague X, Menendez C, Loscertales MP, et al. HPV genotypes in rural Mozambique. Lancet 2001; 358:1429-1430.
30. Kols A, Sherris J. HPV vaccines: Promises and challenges. PATH. 2000.
31. Galloway DA. Papillomavirus vaccines in clinical trials. Lancet Infect Dis 2003; 3:469-475.
32. Harper DM, Franco EL, Wheeler C, et al. Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: A randomized controlled trial. Lancet 2004; 364:1757-1765.
33. Goldie SJ, Grima D, Kohli M, Wright TC, Weinstein M, Franco E. A comprehensive natural history model of HPV infection and cervical cancer to estimate the clinical impact of a prophylactic HPV 16/18 vaccine. Int J Cancer 2003; 106:896-904.
34. European Consensus Group on Hepatitis B Immunity. Are booster immunizations needed for lifelong hepatitis B immunity? Lancet 2000; 355:561-565.
35. Williamson AL, Marais D, Passmore JA, Rybicki E. HPV infection in Southern Africa: Prevalence, immunity and vaccine prospects, IUBMB Life 2002; 53:253-258.
36. Gauri V, Khaleghian. Immunization in Developing Countries, Its Political and Organizational Determinants, Policy Research Working Paper. World Bank Development Research Group, 2002.
37. Banatvala J, Damme PV, Hattum JV, on behalf of the European Consensus Group on Hepatitis B Immunity. Boosters for hepatitis B. Lancet 2000; 356:337-338.
38. Brugha R, Starling M, Walt G. GAVI, and the first steps: Lessons for the Global Fund. Lancet 2002; 359:435-438.
39. Wenger J. Vaccines for the developing world: Current status and future directions. Vaccine 2001; 19:1588-1591.
40. Hughes JP, Garnett GP, Koutsky L. The theoretical population-level impact of a prophylactic human papilloma virus vaccine. Epidemiology 2002; 13:631-639.
41. Global Alliance for Vaccines and Immunizations (GAV1) Fact sheet #169, 2001. Available at: http://www.who.int/inf-fs/en/factl69.html.
42. UNICEF Statistics Global and Regional Trends in Immunization Coverage. UNICEF End-Decade Databases. WHO/UNICEF, 2001. Available at: www.childinfo.org/eddb/immuni/trends.
43. Shann F, Steinhoff MC. Vaccines for children in rich and poor countries. Lancet 1999; 354:7-11.
44. The World Health Report. Geneva: World Health Organization, 1998:62.
45. Mahoney FJ. Update on diagnosis, management and prevention of hepatitis B virus infection. Clin Microbol Rev 1999; 12:351-366.
46. Kane MA. Global status of hepatitis B immunization. Lancet 1996; 348:696.
47. Dawar M, Dobson S, Kailos A, Lajeunesse C, Weatherill S, Daly P. Measuring hepatitis B uptake in a new universal infant program. Can J Public Health 2002; 93:281-284.
48. Louther J, Feidman J, Rivera P, et al. Hepatitis B vaccination program at a New York hospital: Seroprevalence, seroconversion and declination. Am J Infect Control 1998; 26:423-427.
49. Hanacik LJ, Franson TR, Gollup JD, Rytel MW. Implementing a successful hepatitis B vaccination program. Infect Control 1985; 6:306-309.
50. Central Statistics Authority (Ethiopia & ORC MACRO, 2001). Ethiopia Demographic & Health Survey 2000. Addis Abba, Ethiopia & Calverton, MD: Central Statistical Authority & ORC Macro.
51. International Institute for Population Sciences (HPS) and ORC MACRO, 2000. National Family Health Survey (NFHS-2) (1998-1999). Mumbai, India: IIPS.
52. World Education Report 2000, Paris, UNESCO Publishing, 2000. Available at: www.unesco.org/education/information/wer/.
53. Rosenthal SL, Kottenhahn RK, Biro FM, Succop PA. Hepatitis B acceptance among adolescents and their parents. J Adolesc Health 1995; 17:248-254.
54. Kirby D. The impact of schools and school programs upon adolescent sexual behavior. J Sex Res 2002; 39:27-33.
55. Kramer A, Prufer-Kramer L. Experience with the new German hepatitis B vaccination strategy since 1995. Int J STD AIDS 2002; 13:35-37.
56. Zimmerman RK, Middleton DB, Burns IT. Routine vaccination across the life span. J Fam Pract 2001; 50(suppl):S1-S20.
57. Zimet GD, Mays RM, Winston Y, Kee R, Dickes J, Su L. Acceptability of human papillomavirus immunization. J Womens Health Gend Based Med 2000; 9:47-50.
58. Bodenheimer H, Fulton J, Kraner P. Acceptance of hepatitis B vaccine among hospital workers. Am J Public Health 1986; 76:252-255.
59. Zimet GD, Liau A, Fortenberry JD. Health beliefs and intention to get immunized for HIV. J Adolesc Health 1997; 20:354-359.
60. Lazcano-Ponce E, Rivera L, Arillo-Santillan E, Salmeron J, Hernandez-Avila M, Munoz N. Acceptability of a human papillomavirus (HPV) trial vaccine among mothers of adolescents in Cuernavaca, Mexico. Arch Med Res 2001; 32:243-247.
61. Hoover DR, Carfioli B, Moench EA. Attitudes of adolescents/young adult women towards human papillomavirus vaccinations and clinical trials. Health Care Women Int 2000; 21:375-391.
62. Waller J, McCaffery K, Forrest S, Szarewski A, Cadman L, Wardle J. Awareness of human papillomavirus among women attending a well woman clinic. Sex Transm Infect 2003; 79:320-322.
63. Paavonen J, Haltunen M, Hansson BG, Nieminen P, Rostila T, Lehtinen M. Pre requisites for human papillomavirus vaccine trial: Results of feasibility studies. J Clin Virol 2000; 19:25-30.
64. Miller MA, Flanders WD. A model to estimate the probability of hepatitis B and hemophilus influenza type B vaccine uptake into national vaccination programs. Vaccine 2000; 18:2223-2230.
65. Torvaldsen S, McIntyre PB. Observational methods in epidemiological assessment of vaccine effectiveness. Commun Dis Intell 2002; 26:451-457.
66. Savy V. Regional perspectives in influenza surveillance in South America. Vaccine 2002; 20:547-49.
67. Wilson BC, Moyer L, Schmid G, et al. Hepatitis B vaccination in sexually transmitted disease (STD) clinics: A survey of STD programs. Sex Transm Dis 2001; 28:148-152.
68. Foege WH, Eddins DL. Mass vaccination programs in developing countries. Prog Med Virol 1973; 15:205-243.
69. Barton JH. Financing of vaccines. Lancet 2000; 355:1269-1270.
70. Milstein JB, Batson A. Funding for vaccination. Lancet 1998; 352:579.
71. Kulasingham SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. JAMA 2003; 290:781-789.
72. Denny L, Kuhn L, Pollack A, Wainwright H, Wright T. Evaluation of alternative methods of cervical cancer screening for resource-poor settings. Cancer 2000; 89:826-833.
73. Denny L, Kuhn L, Pollack A, Wright TC Jr. Direct visual inspection for cervical cancer screening; an analysis of factors influencing test performance. Cancer 2002; 94:1699-1707.
74. Bradley J, Barone M, Mahe C, Luciani S, Lewis R. Delivering cervical cancer prevention services in low resource settings. Int J Gynaecol Obstet 2005; 895:S21-S29.
75. Belinson JL, Pretorius RG, Zhang WH, Wu LY, Qiao YL, Elson P. Cervical cancer screening by simple visual inspection after acetic acid. Obstet Gynecol 2001; 98:441-444.
76. Sankaranarayanan R, Shymalakumary B, Wesley R, et al. Visual inspection of the uterine cervix with acetic acid in the detection of cervical carcinoma and its precursors. Cancer 1998; 80:161-163.
77. Sankaranarayanan R, Wesley R, Thara S, et al. Test characteristics of visual inspection with 4% Acetic acid (VIA) and Lugol's Iodine (VILI) in cervical cancer screening in Kerala, India. Int J Cancer 2003; 106:404-408.
78. University of Zimbabwe/JHPIEGO Cervical Cancer Project Visual inspection with acetic acid for cervical-cancer screening: Test qualities in a primary-care setting. Lancet 1999; 353:869-873.
79. Royal Thai College of Obstetricians, Gynecologists (RTCOG), the JHPIEGO Corporation Cervical Cancer Prevention Group. Safety, acceptability, and feasibility of a single-visit approach to cervical cancer prevention in rural Thailand: A demonstration project. Lancet 2003; 361:814-820.